-
Kenny Howell posted an update 6 months ago
Likewise, fuel consumption and emissions are used to investigate environmental impacts. Overall, the results show that AVs in mixed traffic streams can induce behavioral changes in conventional vehicle drivers, with some beneficial effects on safety and the environment. On average, a driver that follows an AV exhibits lower driving volatility in terms of speed and acceleration, which represents more stable traffic flow behavior and lower crash risk. The analysis showed a remarkable improvement in TTC as a result of the notably better speed adjustments of the following vehicle (i.e., lower differences in speeds between the lead and following vehicles) in the second scenario. Furthermore, human-driven vehicles were found to consume less fuel and produce fewer emissions on average when following an AV.Traffic conflicts are heavily correlated with traffic collisions and may provide insightful information on the failure mechanism and factors that contribute more towards a collision. Although proactive traffic management systems have been supported heavily in the research community, and autonomous vehicles (AVs) are soon to become a reality, analyses are concentrated on very specific environments using aggregated data. This study aims at investigating -for the first time- rear-end conflict frequency in an urban network level using vehicle-to-vehicle interactions and at correlating frequency with the corresponding network traffic state. The Time-To-Collision (TTC) and Deceleration Rate to Avoid Crash (DRAC) metrics are utilized to estimate conflict frequency on the current network situation, as well as on scenarios including AV characteristics. Three critical conflict points are defined, according to TTC and DRAC thresholds. After extracting conflicts, data are fitted into Zero-inflated and also traditional Negative Binomial models, as well as quasi-Poisson models, while controlling for endogeneity, in order to investigate contributory factors of conflict frequency. Results demonstrate that conflict counts are significantly higher in congested traffic and that high variations in speed increase conflicts. Nevertheless, a comparison with simulated AV traffic and the use of more surrogate safety indicators could provide more insight into the relationship between traffic state and traffic conflicts in the near future.Dynamic tracking of variant frequencies among viruses circulating in the global pandemic has revealed the emergence and dominance of a D614G mutation in the SARS-CoV-2 spike protein. To address whether pandemic SARS-CoV-2 G614 variant has evolved to become more pathogenic, we infected adult hamsters (>10 months old) with two natural SARS-CoV-2 variants carrying either D614 or G614 spike protein to mimic infection of the adult/elderly human population. Hamsters infected by the two variants exhibited comparable viral loads and pathology in lung tissues as well as similar amounts of virus shed in nasal washes. Altogether, our study does not find that naturally circulating D614 and G614 SARS-CoV-2 variants differ significantly in pathogenicity in hamsters.
We aim to directly compare changes in lymphocyte subpopulations between chimeric (rituximab) and humanised (ocrelizumab) anti-CD20 antibodies in multiple sclerosis (MS).
In this retrospective analysis of prospectively collected data, we included 88 patients with MS, treated with rituximab (n=50) or ocrelizumab (n=38). Selleckchem Avexitide We used flow cytometry in the peripheral blood to count total lymphocytes and lymphocytes expressing different phenotypic markers (CD4, CD8, CD19, CD20, CD4/CD8 ratio), before treatment and after 1, 3 and 6 months.
On linear mixed effect regression models, after 1, 3 and 6 months, patients treated with rituximab and with ocrelizumab were similar in total lymphocyte count, CD19 lymphocytes, CD20 lymphocytes and CD4/CD8 ratio. However, patients treated with ocrelizumab presented with lower CD4 T lymphocytes and CD8 T lymphocytes after 1, 3 and 6 months (all p<0.05). No between-treatment difference in EDSS progression was found.
B-cell levels in the peripheral blood were equally decreased by rituximab and ocrelizumab. On the contrary, CD4 and CD8 T lymphocyte reduction was more pronounced in ocrelizumab, when compared with rituximab, suggesting a broader immunomodulatory effect for the humanised antibody to be confirmed and correlated with clinical efficacy in the long term.
B-cell levels in the peripheral blood were equally decreased by rituximab and ocrelizumab. On the contrary, CD4 and CD8 T lymphocyte reduction was more pronounced in ocrelizumab, when compared with rituximab, suggesting a broader immunomodulatory effect for the humanised antibody to be confirmed and correlated with clinical efficacy in the long term.It was aimed to analyze the effectiveness of the Laboratory Risk Indicator for Necrotizing Fasciitis (LRINEC) score in predicting amputation and mortality in diabetic foot infection (DFI). Data of 416 patients who were hospitalized for DFI were recorded retrospectively. LRINEC scores were calculated for each patient from laboratory data. The diagnostic performance of LRINEC score was investigated in amputated/nonamputated and survived/deceased patient groups. Median LRINEC score of patients who underwent amputation was higher than those without amputation (P less then 0.001). The area under the curve (AUC) value for LRINEC score was 0.638 with the cut-off point of ≥5 in predicting amputation. Median LRINEC score of deceased patients was higher than those who survived (P= 0.022). AUC value for LRINEC score was 0.663 with the cut-off point of ≥7 in predicting mortality. LRINEC score may be a promising scoring system in predicting both amputation and mortality in DFI.Although multidrug therapy is considered an effective treatment for leprosy, antimicrobial resistance is a serious concern. We performed a systematic review of studies on the diagnostic accuracy and screening of tests for antimicrobial resistance in leprosy. This review was registered in PROSPERO (CRD42020177958). In April 2020, we searched for studies in the PubMed, EMBASE, Web of Science, Scopus, Scielo, and LILACS databases. A random effects regression model was used for the meta-analysis. We included 129 studies. Molecular tests for dapsone resistance had a sensitivity of 78.8% (95% confidence interval = 65.6-87.9) and a specificity of 97.0% (95% CI = 94.0-98.6). Molecular tests for rifampicin resistance had a sensitivity and specificity of 88.7% (95% CI = 80.0-93.9) and 97.3% (95% CI = 94.3-98.8), respectively. Molecular tests for ofloxacin resistance had a sensitivity and specificity of 80.9% (95% CI = 60.1-92.3) and 96.1% (95% CI = 90.2-98.5), respectively. In recent decades, no increase in the resistance proportion was detected.